期刊
NEUROUROLOGY AND URODYNAMICS
卷 34, 期 5, 页码 413-419出版社
WILEY
DOI: 10.1002/nau.22598
关键词
idiopathic overactive bladder; meta-analysis; onabotulinumtoxinA; randomized controlled trial
Aim: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug for treating idiopathic OAB. Methods: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of onabotulinumtoxinA for the treatment of idiopathic OAB. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Results: Eight publications involving a total of 1,320 patients were used in the analysis, including six RCTs that compared onabotulinumtoxinA with placebo. OnabotulinumtoxinA significantly decreased the mean number of urinary incontinence (UI) per day -2.77 versus -1.01 (the standardized mean difference (SMD)=-1.68, 95% CI=-2.06 to -1.31, P<0.00001); the mean number of micturitions per day -1.61 versus -0.87 (SMD=-1.82, 95% CI=-2.61 to -1.02, P<0.00001); maximum cystometric capacity (MCC) 91.39 versus 32.32 (SMD=63.82, 95% CI=38.14 to 89.50, P<0.00001) and volume voided 44.29 versus 7.36 (SMD=33.05, 95% CI=22.45 to 43.66, P<0.00001) versus placebo and 29.20% versus 7.95% of patients became incontinence-free (odds ratio [OR]=4.89, 95% confidence interval [CI]=3.11 to 7.70, P<0.00001). Safety assessments primarily localized to the urinary tract indicated onabotulinumtoxinA were often associated with complications resulting from postvoid residuals (PVR; P<0.00001), urinary tract infections (UTI; P<0.00001) and clean intermittent catheterization (CIC; P<0.00001). Conclusion: This meta-analysis indicates that onabotulinumtoxinA to be an effective treatment for idiopathic overactive bladder symptoms with side effects primarily localized to urinary tract. (C) 2014 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据